Exposure to Neurotoxins as Risk Factors for ALS

Amyotrophic lateral sclerosis

Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS Adenosine 2A Receptor Antagonism and AIH in ALS Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS Remote Pulmonary Function Testing and Nurse Coaching in ALS Coping Effectiveness Training for ALS Exposure to Neurotoxins as Risk Factors for ALS Assessment of Voluntary and Reflex Cough in Patients With ALS Non-invasive Brain Stimulation for the Treatment of Depression Symptoms in ALS ECoG Direct Brain Interface for Individuals With Upper Limb Paralysis Trial of Oxaloacetate in ALS Safety Study of Oral Edaravone Administered in Subjects With ALS Neuromuscular Ultrasound in ALS A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)